(888) 863-2530(888) 863-2530

Study Shows Gynecomastia Risk Higher with Risperdal than Rival Drugs

To date, more than 1,000 Risperdal gynecomastia lawsuits have joined the multidistrict litigation established in Pennsylvania courts alone. These lawsuits are filed by men, many of them young men, who claim that side effects of the popular antipsychotic drug caused them to develop excessive breast tissue. Now, a study released last month has found that the risk of gynecomastia is much higher with Risperdal than with rival medications such as Zyprexa and Seroquel.

The study, published in the Journal of Clinical Psychopharmacology, investigated the histories of 8,000 men with gynecomastia. The researchers determined that males who take Risperdal are up to 69 percent more likely to develop gynecomastia. They also found that the risk of developing gynecomastia is 40 percent greater with Risperdal than with competitive antipsychotics.

In Risperdal gynecomastia lawsuits, plaintiffs allege that the companies behind this drug, Johnson & Johnson and subsidiary Janssen Pharmaceuticals, were aware of the likelihood of a gynecomastia side effect but did not adequately disclose this risk to the public.

Medically speaking, gynecomastia may not be deemed a serious condition. However, multiple studies and reports have shown that the psychological side effects of male breast development can be devastating and affect patients for a lifetime. Additionally, many men with gynecomastia need to undergo surgical procedures such as liposuction or even mastectomy to restore their bodies’ appearances to a more masculine shape.

If you or a man or boy you love has been diagnosed with gynecomastia which may be a side effect of Risperdal, you are entitled to pursue compensation for your physical, emotional, and financial damages in a dangerous drug lawsuit. For more information on Risperdal gynecomastia lawsuits, please contact an experienced personal injury attorney.